Journal
ANALYTICAL BIOCHEMISTRY
Volume 657, Issue -, Pages -Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ab.2022.114873
Keywords
Ammonia; Hepatic encephalopathy; Cirrhosis; Encephalopathy; Diagnosis; Biomarker
Funding
- MedDay Pharmaceuticals
- Gore
- Alfasigma
- Owkin
Ask authors/readers for more resources
Ammonemia plays a significant role in the development of hepatic encephalopathy in patients with chronic liver diseases. It can not only be used for differential diagnosis but also serve as a prognostic marker, indicating a potential toxic effect of ammonia even in patients without neurological symptoms.
Ammonia is one of the main players in the pathogenesis of hepatic encephalopathy (HE) in patients with chronic liver diseases. The usefulness of measuring ammonemia has been debated since many years. New data reveal that besides helping in the differential diagnosis of HE, ammonemia could be a prognostic marker not only in patients with HE, but also in patients without any neurological symptoms, suggesting a potential toxic role of ammonia beyond the brain. Finally, targeting ammonemia while monitoring therapeutic response could be a way to improve outcomes in patients with HE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available